[go: up one dir, main page]

MX2019005466A - Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. - Google Patents

Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.

Info

Publication number
MX2019005466A
MX2019005466A MX2019005466A MX2019005466A MX2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A
Authority
MX
Mexico
Prior art keywords
formulation
subject
hypercholesterolemia
hypertension
pharmaceutically acceptable
Prior art date
Application number
MX2019005466A
Other languages
English (en)
Inventor
Thai Ngoc
Pollett Jonathan
Original Assignee
Imagine Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma filed Critical Imagine Pharma
Publication of MX2019005466A publication Critical patent/MX2019005466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion provee una composicion que comprende una cantidad terapeuticamente efectiva de un polipeptido, peptido o analogo que corresponde a una o mas de SEQ ID NO(s) 1, 2, 3 o 4, y/o uno o mas de un vehiculo farmaceuticamente aceptable, diluyente farmaceuticamente aceptable y/o excipiente farmaceuticamente aceptable; el polipéptido terapeutico de la presente invencion puede formularse para administracion a un sujeto en necesidad de tratamiento como una formulacion oral, una formulacion parenteral, una formulacion topica, una formulacion acuosa, una formulacion solida, una formulacion liofilizada o una formulación transdermica; se describe tambien un metodo para tratar por lo menos uno de diabetes, y/o hiperglucemia, y/o hipercolesterolemia, y/o hipertension, y/o sindrome metabolico en un sujeto, que comprende: administrar al sujeto un polipeptido de la invencion o formulacion de la invencion.
MX2019005466A 2016-11-13 2017-11-13 Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. MX2019005466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421332P 2016-11-13 2016-11-13
PCT/US2017/061343 WO2018089909A1 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Publications (1)

Publication Number Publication Date
MX2019005466A true MX2019005466A (es) 2019-10-02

Family

ID=62107069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005466A MX2019005466A (es) 2016-11-13 2017-11-13 Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.

Country Status (9)

Country Link
US (2) US10548941B2 (es)
EP (1) EP3538124A4 (es)
JP (3) JP2020502056A (es)
KR (1) KR102497242B1 (es)
CN (1) CN110087666B (es)
AU (2) AU2017357052B2 (es)
BR (1) BR112019009511A2 (es)
MX (1) MX2019005466A (es)
WO (1) WO2018089909A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538124A4 (en) * 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
WO2019138219A1 (en) 2018-01-09 2019-07-18 Imagine Pharma, Llc Use of rps2 peptides for modulating endothelial cell dysfunction
AU2019295576B2 (en) * 2018-06-25 2024-04-04 Imagine Pharma, Llc Compositions and methods for propagating insulin-producing islet cells and therapeutic uses thereof
CN110974943A (zh) * 2019-12-09 2020-04-10 广东药科大学 一种口服胰岛素药物制剂及其制备方法
AU2022349361A1 (en) * 2021-09-22 2024-03-07 Imagine Pharma Llc Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
JP2024545981A (ja) * 2021-12-11 2024-12-17 イマジン ファーマ、エルエルシー 経口投与のための組成物および方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4025395B2 (ja) * 1997-04-09 2007-12-19 花王株式会社 新規ペクチン酸リアーゼ
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AUPR311601A0 (en) * 2001-02-15 2001-03-08 Adp Pharmaceutical Pty Limited Matrix gene expression in chondrogenesis
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
JP2005517400A (ja) * 2001-07-10 2005-06-16 ジーン ロジック インコーポレイテッド 心臓毒分子毒性モデリング
EP2275125A3 (en) * 2002-04-02 2011-03-09 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
CA2527957A1 (en) * 2003-06-02 2005-01-06 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能
US20090048199A1 (en) * 2007-03-09 2009-02-19 Hiberna Corporation Hibernation-Related Genes and Proteins, Activators and Inhibitors Thereof and Methods of Use
EP2424877A4 (en) * 2009-04-28 2013-01-02 Harvard College SUPRAGELADENE PROTEINS FOR CELL PENETRATION
US20140080824A1 (en) 2010-10-21 2014-03-20 New York University Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
EP2638400A4 (en) 2010-11-12 2014-05-07 Univ Johns Hopkins ALBUMIN-RELATED PROTEIN / PEPTIDE COMPLEX AS BIOMARKER FOR DISEASE
HUE029022T2 (en) 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
US20160219910A1 (en) * 2013-09-25 2016-08-04 Pronutria, Inc. Compositions and Formulations for Maintaining and Increasing Muscle Mass, Strength, and Performance and Methods of Production and Use Thereof
EA036985B1 (ru) * 2014-10-31 2021-01-25 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы лечения метаболических расстройств
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3538124A4 (en) 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
WO2019138219A1 (en) * 2018-01-09 2019-07-18 Imagine Pharma, Llc Use of rps2 peptides for modulating endothelial cell dysfunction

Also Published As

Publication number Publication date
US20200222499A1 (en) 2020-07-16
US10751384B2 (en) 2020-08-25
JP2020502056A (ja) 2020-01-23
KR20190084070A (ko) 2019-07-15
JP2023071670A (ja) 2023-05-23
JP2025163025A (ja) 2025-10-28
WO2018089909A1 (en) 2018-05-17
CN110087666B (zh) 2024-04-30
KR102497242B1 (ko) 2023-02-09
US10548941B2 (en) 2020-02-04
EP3538124A4 (en) 2020-07-22
AU2022203741A1 (en) 2022-06-23
CA3041362A1 (en) 2018-05-17
EP3538124A1 (en) 2019-09-18
JP7711967B2 (ja) 2025-07-23
AU2017357052B2 (en) 2022-03-24
BR112019009511A2 (pt) 2019-07-30
US20180133280A1 (en) 2018-05-17
AU2017357052A1 (en) 2019-05-02
CN110087666A (zh) 2019-08-02
AU2022203741B2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
MX2019005466A (es) Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.
RU2471867C2 (ru) Гиалуронидаза и способ ее применения
MX2024009997A (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un farmaco
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
IL308807B2 (en) Combination therapy for treating cancer
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
ATE258444T1 (de) Therapeutische chemokine rezeptor antagonisten
JP2015517488A5 (es)
WO2012012600A3 (en) Peptide compounds for regulating the complement system
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
RU2011108486A (ru) ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
FI3998067T3 (fi) Koostumukset ja menetelmät homokystinurian hoitoon
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA200700178A1 (ru) Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
RU2015119472A (ru) Терапевтическое средство для бокового амиотрофического склероза
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста